Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression | Synapse
April 27, 2026
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression
Key Points
To evaluate whether baseline IL-6 levels can predict response to esketamine in individuals with treatment-resistant depression.
Assessed baseline IL-6 levels in subjects diagnosed with treatment-resistant depression.
Evaluated response to esketamine treatment based on IL-6 measurements.
High baseline IL-6 levels correlate with positive response to esketamine treatment.
Suggests potential for using IL-6 as a biomarker to guide personalized treatment strategies.
Abstract
Baseline IL-6 may predict response to esketamine in TRD, highlighting the potential role of inflammation in treatment resistance and supporting biomarker-guided personalized interventions.